How to transfer my Wegovy prescription to New York

Last Updated: December 17, 2024

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I get these prescriptions through telehealth? The short answer is yes—in most cases, you can legally receive weight loss medication through telemedicine across the United States. But the details vary by state, and understanding the rules can help you access safe, effective care.

This comprehensive guide walks you through federal and state regulations, provider qualifications, patient eligibility, and what to expect from a legitimate telehealth weight loss program.

Understanding Federal Telehealth Rules for Weight Loss Medications

GLP-1 Medications Are Not Controlled Substances

Here’s the most important thing to know: Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This distinction is crucial because it means the Ryan Haight Act—which normally requires an in-person examination before prescribing controlled medications via telemedicine—does not apply to these weight loss drugs.

While the DEA has extended COVID-era telehealth flexibilities for controlled substances (like Adderall or anxiety medications) through December 31, 2025, these extensions don’t actually affect GLP-1 prescribing. These medications have always been available via telehealth under federal law, provided a valid patient-provider relationship is established.

What ‘Valid Patient-Provider Relationship’ Means

Federal regulations and state medical boards require that telehealth providers establish a legitimate clinical relationship before prescribing. This typically involves:

• A live video consultation (not just a questionnaire or chat)
• Comprehensive medical history review including current medications, allergies, and past medical conditions
• Assessment of your weight loss goals and eligibility based on BMI and health conditions
• Discussion of risks, benefits, and alternatives to medication therapy
• A treatment plan that includes lifestyle modifications alongside medication

Reputable telehealth platforms like Klarity Health ensure these standards are met through thorough initial consultations with licensed healthcare providers.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Telehealth Prescribing Rules

While federal law allows telehealth prescribing of GLP-1 medications, states impose their own additional requirements. Some states require an initial in-person examination, while others fully embrace virtual care from start to finish.

States Requiring Initial In-Person Exams

Several states mandate that patients have at least one in-person visit before or shortly after starting weight loss medication via telehealth:

Arkansas has some of the nation’s strictest telemedicine regulations. Providers must perform an initial in-person examination to establish a valid patient-provider relationship. While proposals to ease these restrictions have been under review, as of late 2025, the in-person requirement remains in effect.

Delaware requires an initial physical examination before prescribing weight loss medications via telehealth. After the first visit, follow-up consultations can be conducted virtually.

Georgia mandates an in-person exam prior to telehealth prescribing. Notably, Georgia expanded NP/PA prescribing authority in 2024, now allowing these providers to prescribe Schedule II controlled substances with physician delegation—though this doesn’t eliminate the in-person requirement for obesity treatment.

Mississippi requires patients to be seen in person at least once for an initial evaluation before weight management therapy can continue via telehealth. The state is currently considering legislation to grant nurse practitioners independent practice authority, which could expand access.

New Jersey has comprehensive requirements: providers must conduct an extensive initial evaluation including physical exam, laboratory tests, psychological screening, and documentation of a personalized diet and exercise plan. This initial assessment must be thorough enough to identify contraindications and establish appropriate monitoring.

North Dakota expects a hands-on initial evaluation for weight-loss treatment, consistent with state medical board guidance. After establishing care in person, telehealth follow-ups are permitted.

South Carolina requires an initial in-person visit and periodic evaluations. State obesity treatment policy emphasizes the importance of physical assessment before prescribing weight loss medications.

Texas generally expects an initial in-person exam before prescribing weight loss medications, though this isn’t explicitly mandated by statute. Texas has very strict oversight of prescriptive authority, requiring physician agreements for NPs and PAs. The state’s standard of care typically dictates baseline in-person evaluation.

Virginia has detailed requirements from its Board of Medicine: providers must perform an initial physical examination, obtain laboratory work, conduct cardiovascular risk assessment, and develop a personalized diet and exercise plan. A follow-up visit is mandated within 30 days of starting therapy.

States Allowing Fully Virtual Care

Many states permit telehealth prescribing of weight loss medications without requiring any in-person visits:

California explicitly permits telehealth exams as sufficient for establishing care. With NPs gaining full practice authority after three years of experience, California offers robust telehealth access for weight management.

Connecticut has permanent telehealth laws that don’t require in-person visits. However, the state does mandate that obesity treatment include behavioral counseling and a documented diet and exercise plan.

Florida doesn’t require physical exams to be conducted in person, but does impose specific conditions: patients must have BMI ≥30, and follow-up visits are required at least every three months during treatment.

Illinois allows fully virtual care with no special in-person requirements beyond establishing a valid telehealth relationship. The state does require e-prescribing for all medications.

New York permits telehealth exams to suffice for prescribing, with NPs able to practice independently after 3,600 hours of supervised practice. Mandatory e-prescribing has been in effect since 2016.

Pennsylvania has no in-person mandate for GLP-1 prescribing via telehealth. However, NPs still require physician collaboration agreements (full practice authority regulations are pending).

Utah encourages but doesn’t strictly require an initial in-person exam. The state recently expanded NP autonomy in 2023, improving telehealth access.

Washington is among the most progressive telehealth states, with no in-person requirements and full NP practice authority. The state’s My Health My Data Act also provides strong privacy protections for telehealth weight loss data.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physicians (MDs and DOs)

All states allow licensed physicians to prescribe GLP-1 weight loss medications via telehealth, provided they’re licensed in the state where the patient is physically located during the consultation.

Nurse Practitioners and Physician Assistants

Nurse Practitioners (NPs) and Physician Assistants (PAs) can prescribe these medications in all 50 states, but their level of autonomy varies significantly:

Full Practice Authority States: As of December 2025, 34 states plus DC grant NPs independent prescriptive authority without physician oversight. These include Arizona, California, Colorado, Connecticut, Hawaii, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Mexico, New York, Oregon, Rhode Island, Utah, Vermont, Virginia, Washington, and others. NPs in these states can evaluate patients and prescribe weight loss medications independently after meeting experience requirements (typically 2-3 years of collaborative practice).

Collaborative Practice States: Many states require NPs and PAs to have a formal collaboration or supervisory agreement with a physician. This includes Arkansas, Florida, Georgia, Illinois, Mississippi, Pennsylvania, South Carolina, and Texas. In these states, telehealth platforms employ both physicians and NPs/PAs working under collaborative agreements to ensure compliance.

What This Means for Patients: When you consult with a telehealth provider, you may see an NP, PA, or MD depending on your state’s regulations and the platform’s provider network. This is completely normal and legal—these clinicians are fully qualified to manage weight loss treatment. Klarity Health only works with appropriately licensed and credentialed providers, so you can trust in the legitimacy of your prescriber regardless of their professional designation.

Understanding GLP-1 Weight Loss Medications

Wegovy (Semaglutide 2.4mg)

FDA-approved specifically for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related health conditions (like high blood pressure or type 2 diabetes).

How It Works: Once-weekly injection that mimics a natural hormone (GLP-1) to reduce appetite, slow stomach emptying, and help regulate blood sugar.

Telehealth Prescribing: Fully legal via telehealth in all states (subject to state-specific requirements above). Not a controlled substance, so no DEA restrictions apply.

Important Note: Following supply shortages that led to compounded versions, the FDA declared the Wegovy shortage resolved in 2025 and banned routine compounding of semaglutide. Only FDA-approved brand-name or authorized generic versions should be dispensed.

Ozempic (Semaglutide 0.5-1mg)

FDA-approved for type 2 diabetes, but widely prescribed off-label for weight loss (it’s the same active ingredient as Wegovy, just at slightly lower approved doses).

Telehealth Considerations: Can be prescribed via telehealth, but providers must document the off-label use rationale and obtain informed consent. Patients should understand this is an off-label application and insurance coverage may differ from Wegovy.

Mounjaro (Tirzepatide)

FDA-approved for type 2 diabetes; the obesity-specific version called Zepbound received FDA approval in late 2023.

How It Works: Dual-action medication targeting both GLP-1 and GIP receptors, potentially offering more robust weight loss than single-action GLP-1 medications.

Telehealth Access: Fully available via telehealth for eligible patients. No controlled substance restrictions.

Patient Eligibility: Who Qualifies for Telehealth Weight Loss Treatment?

Clinical Criteria

Legitimate telehealth providers carefully screen patients to ensure these medications are appropriate and safe. Generally, you may qualify if you meet these criteria:

Body Mass Index (BMI):

• BMI ≥30 (clinical obesity), OR
• BMI ≥27 with at least one weight-related health condition such as:
• Type 2 diabetes or prediabetes
• High blood pressure
• High cholesterol
• Sleep apnea
• Cardiovascular disease

Prior Weight Loss Attempts: Most providers expect you’ve tried lifestyle modifications (diet and exercise) without achieving sustainable weight loss—unless there are medical reasons why conventional approaches aren’t advisable.

Commitment to Lifestyle Changes: These medications work best—and are FDA-approved—as part of a comprehensive program including reduced-calorie diet and increased physical activity. Expect your provider to discuss nutrition and exercise alongside the prescription.

Medical Contraindications

You may not be eligible for GLP-1 medications if you have:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—these carry an FDA black box warning
• Pregnancy or plans to become pregnant (must discontinue at least 2 months before conception)
• Active gallbladder disease or history of pancreatitis
• Severe gastrointestinal disorders such as gastroparesis or inflammatory bowel disease
• History of eating disorders (relative contraindication; requires careful evaluation)
• Diabetic retinopathy complications (for semaglutide specifically)

Realistic Expectations

Common misconceptions that reputable telehealth providers will address:

Myth: ‘I can get Ozempic for vanity weight loss—I just want to drop 10 pounds for vacation.’

Reality: These medications are intended for individuals with clinical obesity or significant health risks related to excess weight. Ethical providers won’t prescribe them for cosmetic purposes or to people at healthy weights.

Myth: ‘These are quick-fix diet pills.’

Reality: GLP-1 medications produce gradual weight loss over several months (typically 1-2 pounds per week at most). They require commitment to lifestyle changes and ongoing medical monitoring. Most patients stay on treatment for a year or longer.

Myth: ‘I can skip follow-up appointments once I have my prescription.’

Reality: Regular monitoring is medically necessary—and legally required in many states. Providers need to assess side effects, adjust doses, monitor labs, and ensure the treatment remains safe and effective.

What to Expect from a Legitimate Telehealth Weight Loss Program

Initial Consultation

A thorough telehealth evaluation should include:

1. Comprehensive Medical Questionnaire: Detailed questions about your medical history, current medications, allergies, previous weight loss attempts, and any symptoms or conditions.

2. Live Video Consultation: A real-time conversation with a licensed provider (not just a chat or automated questionnaire). This typically lasts 20-30 minutes for initial visits.

3. Height/Weight Verification: You’ll report your current measurements. Some platforms may require photo verification or ask you to weigh in during the video call.

4. Risk/Benefit Discussion: Your provider should explain how the medication works, common side effects (nausea, diarrhea, constipation, potential gallstones), and contraindications. You’ll discuss alternatives and why medication may be appropriate for you.

5. Lifestyle Counseling: Expect guidance on nutrition, physical activity, and behavioral strategies alongside medication.

6. Informed Consent: You’ll acknowledge understanding of the treatment, including off-label use if applicable (e.g., using Ozempic for weight loss).

Ongoing Monitoring and Follow-Up

Frequency: Most programs require follow-ups at:

• 1 month after starting (to assess tolerance and early response)
• Every 2-3 months during dose titration
• Every 3 months once at maintenance dose

Some states mandate specific follow-up intervals (Florida requires visits every 3 months; Virginia requires a 30-day check-in).

What’s Monitored:

• Weight loss progress
• Side effects and tolerability
• Blood pressure and heart rate
• Periodic lab work (metabolic panel, liver function, sometimes A1C)
• Signs of gallbladder issues or other complications

Dose Adjustments: GLP-1 medications typically start at a low dose and gradually increase over 12-16 weeks to minimize side effects and find your optimal therapeutic dose.

Prescription and Dispensing

E-Prescribing: Your provider will send your prescription electronically to a pharmacy of your choice. Many states require electronic prescribing (eliminating paper scripts).

Pharmacy Options: Most patients fill prescriptions at traditional retail pharmacies (CVS, Walgreens, local independents) or mail-order pharmacies. Avoid any telehealth service that wants to ship medication directly without involving a licensed pharmacy—this is a major red flag.

Supply and Refills: Initial prescriptions are often for 4 weeks (one month) to assess tolerance. After that, prescriptions may be written for 1-3 months at a time depending on state rules and insurance requirements. Federal law doesn’t limit supply for non-controlled medications, but follow-up appointments are required before refill authorization.

Insurance vs. Cash Pay: These medications can be expensive ($900-$1,300/month without insurance). Some insurance plans cover them for diabetes or obesity; many don’t. Telehealth platforms like Klarity Health accept both insurance and offer transparent cash-pay pricing, helping you understand costs upfront.

How Klarity Health Supports Safe Telehealth Weight Loss Care

At Klarity Health, we’re committed to making evidence-based weight management accessible while maintaining the highest standards of patient safety and regulatory compliance.

Our Approach

Comprehensive Evaluations: Every patient undergoes a thorough medical screening with a licensed provider before receiving any prescription. We don’t cut corners—your safety comes first.

Licensed in Your State: Our providers are licensed in the state where you live, ensuring full legal compliance with state-specific telehealth and prescribing requirements.

Transparent Pricing: We accept both insurance and offer cash-pay options with clear, upfront pricing—no hidden fees or surprise bills.

Provider Availability: We know scheduling matters. Our platform offers convenient appointment times, including evenings and weekends, so you can access care when it fits your life.

Ongoing Support: Weight loss is a journey, not a one-time prescription. We schedule regular follow-ups, monitor your progress, and adjust treatment as needed. You’ll have access to your care team between appointments if questions arise.

Red Flags to Avoid

Unfortunately, the popularity of GLP-1 medications has attracted some unscrupulous operators. Be cautious of any telehealth service that:

❌ Guarantees you’ll get a prescription before evaluating you
❌ Offers compounded or ‘alternative’ versions of semaglutide (FDA banned these for routine use in 2025)
❌ Doesn’t require a live consultation with a licensed provider
❌ Ships medication directly without involving a licensed U.S. pharmacy
❌ Doesn’t schedule follow-up appointments or monitor your treatment
❌ Isn’t transparent about provider credentials or licensing
❌ Promises unrealistic results like ‘lose 30 pounds in 30 days’

Stick with established, reputable telehealth platforms that prioritize your health over quick profits.

Costs and Insurance Coverage

Typical Medication Costs

Without insurance, GLP-1 weight loss medications typically cost:

• Wegovy: $1,300-$1,400/month
• Ozempic: $900-$1,000/month
• Mounjaro/Zepbound: $1,000-$1,200/month

Insurance Coverage

Coverage varies widely:

• Many plans cover these medications for type 2 diabetes (Ozempic, Mounjaro)
• Fewer plans cover obesity treatment (Wegovy, Zepbound)—though coverage is expanding as evidence grows
• Medicare Part D does not currently cover weight loss medications (though coverage for diabetes formulations exists)
• Some states mandate insurance coverage for obesity treatment, which may include these medications

Manufacturer Savings Programs

Pharmaceutical companies offer savings programs that can reduce costs:

• Wegovy Savings Card: May reduce copays to as low as $0-$25/month for eligible commercially insured patients
• Ozempic Savings Card: Similar programs available
• Mounjaro Savings Card: Can significantly reduce out-of-pocket costs

Your Klarity Health provider can help you navigate these options to find the most affordable path forward.

The Future of Telehealth Weight Loss Treatment

Regulatory Outlook

Telehealth for weight management is here to stay. Key trends to watch:

DEA Flexibility Extension: While the current telehealth extension for controlled substances expires December 31, 2025, another extension or permanent rule is expected. This doesn’t directly affect GLP-1 medications (which aren’t controlled), but signals broad federal support for telemedicine prescribing.

TREATS Act: Bipartisan legislation reintroduced in October 2025 would permanently allow telehealth prescribing of certain controlled substances. If passed, this would further cement telehealth as a standard care delivery model.

State Law Evolution: More states are moving toward full practice authority for nurse practitioners and loosening telehealth restrictions. We expect continued expansion of access in 2026 and beyond.

Interstate Licensing: More states are joining interstate licensure compacts, making it easier for providers to be licensed in multiple states and treat patients wherever they live.

Clinical Developments

New Medications: Several next-generation weight loss medications are in late-stage trials, potentially offering even more effective treatments accessible via telehealth.

Expanded Indications: Research continues on GLP-1 medications for cardiovascular protection, fatty liver disease, and other conditions—potentially broadening who qualifies for these treatments.

Improved Monitoring Tools: Remote patient monitoring technology (connected scales, continuous glucose monitors) may integrate with telehealth platforms for even better treatment oversight.

Frequently Asked Questions

Q: Do I need to see a doctor in person before getting weight loss medication through telehealth?

A: It depends on your state. Most states allow fully virtual care, but Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, and Virginia require an initial in-person examination. Check the state-specific table in this guide for details.

Q: Can nurse practitioners prescribe these medications via telehealth?

A: Yes, in all states—though the level of physician oversight required varies. In about 34 states, NPs can prescribe independently after meeting experience requirements. In other states, they work under physician collaboration agreements.

Q: Are compounded versions of semaglutide safe and legal?

A: As of May 2025, the FDA banned routine compounding of semaglutide for weight loss after declaring the shortage resolved. Only FDA-approved brand-name versions should be used. Be very cautious of any provider offering compounded alternatives.

Q: How long will I need to stay on these medications?

A: Most patients require long-term treatment to maintain weight loss. Clinical trials show many people regain weight if medication is stopped. Your provider will work with you to determine the appropriate duration based on your response and health goals.

Q: Will my insurance cover telehealth visits for weight loss?

A: Many insurance plans now cover telehealth visits at the same rate as in-person visits, but policies vary. Klarity Health accepts insurance and can verify your benefits before your appointment. We also offer affordable cash-pay rates.

Q: What if I move to a different state during treatment?

A: Your provider must be licensed in the state where you’re physically located. If you move, Klarity Health can help transition your care to a provider licensed in your new state to ensure continuity of treatment.

Taking the Next Step

If you’re struggling with weight management and meet the clinical criteria for GLP-1 medication therapy, telehealth offers a convenient, effective, and legal pathway to access these treatments—when done correctly.

The key is choosing a reputable provider who prioritizes your safety, follows all state and federal regulations, and provides comprehensive ongoing care beyond just writing prescriptions.

Ready to explore whether telehealth weight loss treatment is right for you?

Klarity Health makes it simple to get started:

• Book an appointment with a licensed provider in your state
• Complete a comprehensive medical evaluation via secure video consultation
• Receive personalized treatment recommendations based on your unique health profile
• Access transparent pricing for both insurance and cash-pay options
• Get ongoing support with regular follow-ups and provider access

Visit Klarity Health today to schedule your consultation and take the first step toward your weight loss goals with expert medical guidance—all from the comfort of home.

References

📅 RESEARCH CURRENCY STATEMENT
Verified as of: December 17, 2025
DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.
States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)

Top Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 (November 15, 2024)
   Drug Enforcement Administration
   https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. COVID-era telehealth prescribing extended (November 18, 2024)
   Axios News
   https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 (November 18, 2024)
   McDermott Will & Emery Law Firm
   https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/

4. Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs (March 27, 2024)
   Goodwin Procter LLP
   https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Know Your State’s Laws Around Semaglutide (April 11, 2025)
   Nextech Healthcare Technology Blog
   https://www.nextech.com/blog/semaglutide-laws-by-state

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a licensed healthcare provider to determine if weight loss medication is appropriate for your individual circumstances. State regulations are subject to change; always verify current requirements in your location.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid